A Study to Find and Confirm the Dose and Assess Safety, Reactogenicity and Immune Response of a Vaccine Against Pandemic H5N1 Influenza Virus in Healthy Younger and Older Adults
Conditions: Influenza, Human Interventions: Biological: Flu Pandemic mRNA_Dose level 1; Biological: Flu Pandemic mRNA_Dose level 2; Biological: Flu Pandemic mRNA_ Dose level 3.; Biological: Flu Pandemic mRNA_ Dose level 4; Biological: Flu Pandemic mRNA_Dose level 5; Biological: Flu Pandemic mRNA_Dose level 6; Biological: Flu Pandemic mRNA_Dose level 7; Drug: Placebo Sponsors: GlaxoSmithKline Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 24, 2024 Category: Research Source Type: clinical trials
Delivering COVID-19 vaccine trials at speed: the implementation of a phase IV UK multi-centre randomised controlled trial to determine safety and immunogenicity of COVID-19 vaccines co-administered with seasonal influenza vaccines (ComFluCOV)
ConclusionThe rapid delivery of ComFluCOV was resource intensive. It was made possible in part due to a unique set of circumstances created by the pandemic situation including measures put in place to support urgent public health research and public support for COVID-19 vaccine research. Elements of the trial could be adopted to increase efficiency in ‘non-pandemic’ situations including working with a clinical trials unit to enable immediate mobilisation of a team of experienced researchers, greater sharing of resources between clinical trials units, use of electronic trial systems and virtual meetings.Trial registrati...
Source: Trials - January 11, 2024 Category: Research Source Type: clinical trials
A Study to Learn How Safe, Tolerable and Capable of Producing an Immune Response is, a Modified RNA Vaccine Against Pandemic Influenza
Conditions: Grippe; Influenza; Vaccines Interventions: Biological: PF-07985819 pdmFlu Vaccine; Biological: Placebo; Biological: Quadrivalent influenza vaccine (QIV) Sponsors: Pfizer Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 21, 2023 Category: Research Source Type: clinical trials
H7HLAII DNA Influenza Vaccine Phase I Trial
Conditions: Influenza A; Pandemic Influenza Intervention: Biological: H7HLAII Sponsor: Oslo University Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
H7HLAII DNA Influenza Vaccine
Conditions: Influenza A; Pandemic Influenza Intervention: Biological: H7HLAII Sponsor: Oslo University Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
H7HLAII DNA Influenza Vaccine
Conditions: Influenza A; Pandemic Influenza Interventions: Biological: H7HLAII Sponsors: Oslo University Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
A Study of mRNA-1018 Pandemic Influenza Candidate Vaccines in Healthy Adults
Condition: Influenza Interventions: Biological: mRNA-1018 for H5N8; Biological: mRNA-1018 for H7N9; Biological: mRNA-1018 for H5 Only; Biological: mRNA-1018 for H7 Only; Biological: mRNA-1018 for H5 Only-CG Sponsor: ModernaTX, Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 2, 2023 Category: Research Source Type: clinical trials
